Open-Label, Multicenter, Global, Dose-Escalation Study

XmAb24306 as a Single Agent and in Combination with Atezolizumab

Percentage of Participants with Adverse Events

18 Years and older

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

Life expectancy >/= 12 weeks

Adequate hematologic and end-organ function

For participants receiving therapeutic anticoagulation: stable anticoagulant regimen

Negative serum pregnancy test for women of childbearing potential

Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy

Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Availability of representative tumor specimens

Pregnant or breastfeeding, or intending to become pregnant during the study

Significant cardiovascular disease

Current treatment with medications that prolong the QT interval

Known clinically significant liver disease

Poorly controlled Type 2 diabetes mellitus

Symptomatic, untreated, or actively progressing CNS metastases

History of leptomeningeal disease

History of malignancy other than disease under study within 3 years prior to screening

Active or history of autoimmune disease or immune deficiency

Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus infection

Positive for HIV infection

Prior allogeneic stem cell or solid organ transplantation